EGFR and central nervous system cancer: It is unknown whether CAR T cells can control infiltrative gliomas without injuring the surrounding brain parenchyma, and whether ablation of EGFR-expressing glioma cells will provide a selective survival advantage for EGFR-negative malignant cells.